News Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 03/02/21 Summary ToggleClearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD PDF Version 02/24/21 Summary ToggleClearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021 PDF Version 02/23/21 Summary ToggleClearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 PDF Version 02/16/21 Summary ToggleClearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program PDF Version 02/08/21 Summary ToggleClearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting PDF Version 01/12/21 Summary ToggleClearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD PDF Version 01/06/21 Summary ToggleClearside Biomedical Announces Pricing of $12 Million Registered Direct Offering PDF Version 11/16/20 Summary ToggleClearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology PDF Version 11/11/20 Summary ToggleClearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference PDF Version 11/10/20 Summary ToggleClearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update PDF Version Pagination First page First Previous page Page 1 Current page 2 Page 3 Page 4 Next page Last page Last
